Biotech Startups

EditForce develops proprietary PPR gene-editing technology that can modify both DNA and RNA, with applications in medicine, agriculture, and chemical industries. The company aims to advance therapeutic drug development and address challenges in health, food, and environmental sectors.

4 investors

Kringle Pharma develops and manufactures HGF protein-based pharmaceuticals for treating conditions including spinal cord injury, ALS, and vocal cord scarring. The company is a spin-out of Osaka University and Keio University focused on drug development in the biotech sector.

4 investors

Toregem Biopharma is a Kyoto University spin-off developing a tooth-regeneration drug based on a humanized anti-USAG-1 antibody that aims to regrow teeth with a single injection. It initially targets patients with congenital tooth agenesis (a rare genetic condition) and ultimately aims to treat tooth loss from decay or periodontal disease.

4 investors

Rege Nephro develops regenerative medicine therapies for kidney disease, focusing on nephron progenitor cell research and differentiation from iPS cells. The company aims to commercialize treatments for patients with kidney disorders and reduce reliance on dialysis and transplantation.

4 investors

Buzzreach is a Japanese startup that builds SaaS platforms connecting pharmaceutical companies and medical institutions with patients to support clinical trials and post-launch marketing. It promotes a "DRO" (Digital Research Organization) model using patient-matching via electronic medical records, AI-generated trial documents, decentralized clinical trials, and a patient-centric social network called "miilike."

4 investors

Digzyme develops novel enzymes and bioprocesses to order, providing enzyme libraries, sample supply, IP licensing, and support for scale-up, commercialization, and regulatory approvals. It serves industrial clients seeking custom enzyme solutions in the biotech sector.

4 investors

MOLCURE uses AI models trained on large experimental datasets to design molecules and accelerate drug discovery, working in collaboration with pharmaceutical partners. Its multidisciplinary team of machine learning scientists, biochemists, and bioinformaticians focuses on antibody and drug design.

4 investors

PURMX Therapeutics develops nucleic acid medicines as anti-cancer drugs based on microRNA research and the concept of an "ageing switch" to induce ageing in cancer cells. The Japanese pharmaceutical venture handles drug development functions including non-clinical research, clinical development, CMC, and regulatory affairs.

4 investors

Fermenstation develops and manufactures ethanol and food ingredients from food waste and other unused biomass through fermentation, and provides OEM/ODM production of cosmetics and sundry goods. Based in Japan, it also pursues co-creation businesses using unused resources.

4 investors

PRISM BioLab is a biotechnology company that develops PepMetics, a proprietary drug discovery platform of small molecules designed to mimic α-helix or β-turn peptides, aiming to target proteins previously considered "undruggable." The company maintains a screening library of over 20,000 compounds and partners with pharmaceutical firms on drug discovery programs.

3 investors

1Cell.ai develops an AI-driven, single-cell multi-omics and ctDNA platform for high-resolution tumor profiling, non-invasive cancer diagnostics, and biomarker discovery. It serves clinicians, oncology researchers, and biopharma partners across cancer care and drug development.

3 investors

310 AI develops generative AI foundation models for biology, including a molecular programming model that generates protein sequences from text descriptions of protein function. The company works toward making programmable biology a practical tool for solving real-world problems.

3 investors

5Metis is a discovery-stage company developing boron-based molecules for crop protection, running medicinal/discovery chemistry and toxicity testing programs to invent new agricultural active ingredients. Its R&D team is based in Research Triangle Park, North Carolina.

3 investors

A clinical-stage biopharmaceutical company developing investigational therapies for patients with liver and cardiometabolic diseases, with a lead candidate (pegozafermin) being evaluated for metabolic dysfunction-associated steatohepatitis and severe hypertriglyceridemia.

3 investors

A-SEEDS is a Shinshu University spin-out developing non-viral gene-modified immune cell therapies, including non-viral CAR-T cell products, to treat pediatric and young-adult cancers, including solid tumors, that lack effective treatments. The company focuses on advancing basic research through non-clinical development into clinical application of these cancer cell therapies.

3 investors

AbClon is a biotech company developing new therapeutics, including advanced gene and cell therapies and antibody-based treatments. Its work centers on CAR-T cell therapy and antibody discovery platforms for human disease.

3 investors

AbilityPharma develops innovative oncology therapies that induce autophagy to treat various cancers and address unmet medical needs. The company has advanced therapies including ibrilatazar (ABTL0812) through clinical trials for lung cancer, pancreatic cancer, and other tumor types.

3 investors

ABK Biomedical is a clinical-stage medical device company that develops x-ray visible glass microspheres for Y-90 radioembolization and embolic treatment of cancers such as liver cancer. Spun out of Dalhousie University, it serves interventional oncology and radiology applications.

3 investors

AbolerIS Pharma develops therapeutic approaches that regulate the immune system by inducing immune tolerance while preserving useful immune responses, targeting inflammatory, autoimmune, and degenerative diseases. It is a biotech company working on drug candidates based on regulatory T cell research.

3 investors

Abzena is an integrated CDMO and CRO providing end-to-end development and cGMP manufacturing services for complex biologics and bioconjugates, including ADCs, AOCs, bispecifics, and HPAPIs. It serves biotech, academic, and pharmaceutical customers across the drug development lifecycle from discovery through commercial manufacturing.

3 investors

Accure Health is a company focused on developing treatments to improve the lives of patients and their relatives affected by central nervous system (CNS) diseases. It operates in the biotech sector.

3 investors

Achieve is a specialty pharmaceutical company developing and commercializing cytisinicline as a treatment for nicotine dependence, aimed at helping people who smoke quit. It targets the global smoking health problem through this drug candidate.

3 investors

Achillion conducts research and development focused on addressing rare disease challenges through investigation of new therapeutic targets, modalities, and technologies. The company serves rare disease patients and their families globally.

3 investors

Achira builds molecular world models that blend geometric deep learning, physics, and quantum chemistry to advance drug discovery and materials design. The company combines AI and physical simulation to enable out-of-sample prediction for biomolecular applications.

3 investors